# US 2019/0292588 A1 · Methods for treating barrett's metaplasia and esophageal adenocarcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0292588 A1
- Document ID: US20190292588A1
- Status: Published application
- Kind: A1
- Application number: 16/166,486
- Filed: 2018-10-22
- Published: 2019-09-26
- Earliest claimed: 2011-12-01
- Assignees: Interpace Diagnostics Corporation
- Applicants: Interpace Diagnostics Corporation
- Inventors: Eric Matthew Gayle Ellsworth; Sydney David Finkelstein; Sara Ann Jackson; Brendan Corcoran; Dennis Morgan Smith
- Web page: https://patentgrep.com/patent/US20190292588A1

## CPC

- C12Q 1/6869: Methods for sequencing
- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61B 18/02: by cooling, e.g. cryogenic techniques
- A61B 18/12: by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B 2018/00488: {Esophagus}
- A61N 2005/0609: {Stomach and/or esophagus}
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Disclosed herein are methods for treating Barrett's metaplasia and esophageal adenocarcinoma and methods for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A method for treating subject with a high risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma, the method comprising:
determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma in a subject, by:
amplifying DNA sequences in microsatellite regions 1p (CMM1, Lmyc), 3p (VHL, OGG1), 5q (MCC, APC), 9p (CDKN2A, CDKN2B), 10q (PTEN, MXI1), 17p (TP53), 17q (NME1), 18q (DCC), and 21q, 22q (NF2) from a biological specimen from the subject;
detecting mutations in the microsatellite regions of the amplified DNA sequences;
categorizing clonality of each mutation, wherein categorizing clonality of each mutation comprises assigning one of three categories selected from the group consisting of no clonality, low clonality and high clonality, wherein high clonality is assigned where loss of heterozygosity is present in greater than about 75% of DNA analyzed, low clonality is assigned where loss of heterozygosity is present in about 50% to about 75% of DNA analyzed; and no clonality is assigned where loss of heterozygosity is present in less than about 50% of DNA analyzed;
calculating a mutational load based on the sum of low and high clonality mutations; assigning the subject to a risk category to a high mutational load risk category when the subject has a mutational load greater than or equal to 1.75; and
administering to the subject that is assigned to the high mutational load risk category at least one treatment modality selected from endoscopic mucosal resection, endoscopic submucosal dissection, a therapeutically effective amount of radiofrequency ablation, a therapeutically effective amount of cryoablation, or a therapeutically effective amount of photodynamic therapy.

### Claim 58 (depends on 57)

The method of claim 57, wherein the subject is a human diagnosed with Barrett's esophagus.

### Claim 59 (depends on 57)

The method of claim 57, wherein the biological specimen is a mucosal lining of the esophagus.

### Claim 60 (depends on 57)

The method of claim 57, wherein amplifying DNA sequences comprises:
selecting a primer pair corresponding to a specific microsatellite region;
adding the primer pair to the DNA sequences;
and performing quantitative polymerase chain reaction on the DNA sequences with the primer.

### Claim 61 (depends on 57)

The method of claim 57, wherein detecting mutations comprises determining the sequence of the amplified DNA and comparing the amplified DNA to a known wild type control sequence for the specific microsatellite region and identifying differences between the sequence of the amplified DNA and the known wild type control sequence.

### Claim 62 (depends on 57)

The method of claim 57, wherein DNA microsatellite instability is determined by the presence of at least one of the shortening and lengthening of a DNA microsatellite region.

### Claim 63 (depends on 57)

The method of claim 57, wherein the method is independent of a histological standard.

### Claim 64 (depends on 57)

The method of claim 57, wherein the biological specimen is a biopsy sample, fine needle aspirate sample, a cytology sample, a frozen tissue simple, or a fixed tissue sample.

### Claim 65 (depends on 57)

The method of claim 57, further comprising removing the biological specimen from the subject prior to the amplifying step.

### Claim 66

A method for determining mutational load as a predictor of the risk of disease progression from Barrett's metaplasia to esophageal adenocarcinoma in a subject, the method comprising:
amplifying DNA sequences from a biological specimen from the subject;
detecting mutations in microsatellite regions of the amplified DNA sequences;
categorizing clonality of each mutation;
calculating a mutational load based on the sum of low and high clonality mutations; wherein DNA microsatellite instability at a single locus is defined as 0.75z1, and wherein DNA microsatellite instability at multiple loci is defined as 0.75z1+0.5z2, wherein z1 represent a single locus displaying DNA microsatellite instability and z2 is the number of loci displaying DNA microsatellite instability greater than 1 locus; wherein the score for low clonality is 0.5x, wherein x is the number of low clonality mutations and the score for high clonality is y, wherein y is the number of high clonality mutations; and wherein the overall mutational load is y+0.5x+0.75z1+0.5z2;
comparing the mutational load with a series of pre-determined mutational load cut-offs defining risk categories; and
assigning the subject to a risk category corresponding to the subject's mutational load, wherein each risk category is indicative of the risk of disease progression.
